JP2013512195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512195A5 JP2013512195A5 JP2012540169A JP2012540169A JP2013512195A5 JP 2013512195 A5 JP2013512195 A5 JP 2013512195A5 JP 2012540169 A JP2012540169 A JP 2012540169A JP 2012540169 A JP2012540169 A JP 2012540169A JP 2013512195 A5 JP2013512195 A5 JP 2013512195A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- composition
- vitamin
- administered
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930003316 Vitamin D Natural products 0.000 claims description 29
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 29
- 239000011710 vitamin D Substances 0.000 claims description 29
- 235000019166 vitamin D Nutrition 0.000 claims description 29
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 29
- 229940046008 vitamin d Drugs 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 26
- 230000002519 immonomodulatory effect Effects 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 12
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 12
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- -1 3-piperidyl Chemical group 0.000 claims 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 239000011612 calcitriol Substances 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26406209P | 2009-11-24 | 2009-11-24 | |
| US61/264,062 | 2009-11-24 | ||
| US32447310P | 2010-04-15 | 2010-04-15 | |
| US61/324,473 | 2010-04-15 | ||
| PCT/US2010/057951 WO2011066351A1 (en) | 2009-11-24 | 2010-11-24 | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015101583A Division JP5839637B2 (ja) | 2009-11-24 | 2015-05-19 | ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512195A JP2013512195A (ja) | 2013-04-11 |
| JP2013512195A5 true JP2013512195A5 (https=) | 2013-12-12 |
Family
ID=44066895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540169A Withdrawn JP2013512195A (ja) | 2009-11-24 | 2010-11-24 | ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 |
| JP2015101583A Expired - Fee Related JP5839637B2 (ja) | 2009-11-24 | 2015-05-19 | ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015101583A Expired - Fee Related JP5839637B2 (ja) | 2009-11-24 | 2015-05-19 | ビタミンｄ耐性腫瘍細胞においてビタミンｄ感受性を回復させるための免疫調節性化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8841325B2 (https=) |
| EP (1) | EP2504703B1 (https=) |
| JP (2) | JP2013512195A (https=) |
| CA (1) | CA2780998C (https=) |
| MX (1) | MX2012005849A (https=) |
| WO (1) | WO2011066351A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US8841325B2 (en) * | 2009-11-24 | 2014-09-23 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2752124A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer |
| EP1631543A1 (en) | 2003-06-11 | 2006-03-08 | Novacea, Inc. | Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| NZ599825A (en) * | 2007-09-28 | 2014-10-31 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US20120115804A1 (en) * | 2009-03-10 | 2012-05-10 | The John Hopkins University | Compositions and methods for characterizing and treating neoplasia |
| US8841325B2 (en) * | 2009-11-24 | 2014-09-23 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells |
-
2010
- 2010-11-24 US US13/511,002 patent/US8841325B2/en not_active Expired - Fee Related
- 2010-11-24 WO PCT/US2010/057951 patent/WO2011066351A1/en not_active Ceased
- 2010-11-24 MX MX2012005849A patent/MX2012005849A/es active IP Right Grant
- 2010-11-24 CA CA2780998A patent/CA2780998C/en not_active Expired - Fee Related
- 2010-11-24 EP EP10833897.1A patent/EP2504703B1/en not_active Not-in-force
- 2010-11-24 JP JP2012540169A patent/JP2013512195A/ja not_active Withdrawn
-
2014
- 2014-08-12 US US14/457,825 patent/US20150283124A1/en not_active Abandoned
-
2015
- 2015-05-19 JP JP2015101583A patent/JP5839637B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113453684B (zh) | 用于治疗癌症的csf1r抑制剂 | |
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| JP5668219B2 (ja) | 癌治療のための選択的ｅｐ４受容体拮抗物質 | |
| US20190060275A1 (en) | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer | |
| JP2021526133A5 (https=) | ||
| EP3003296B1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| KR20180105685A (ko) | 투카레솔 또는 이의 유사체를 함유하는 조성물 | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| ES2895419T3 (es) | Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso | |
| CN112867512A (zh) | 联合疗法 | |
| US20140051662A1 (en) | Treatment of multiple myeloma with masitinib | |
| AU2006259638B2 (en) | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | |
| KR20180013850A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| KR20150136074A (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| KR20190068519A (ko) | PIKfyve 억제제를 포함하는 조성물 및 RANK 신호전달의 억제와 관련된 방법 | |
| TW201642859A (zh) | Ｍｄｍ２抑制劑及ｂｔｋ抑制劑之倂用治療法 | |
| KR20180118141A (ko) | 암 치료를 위한 조합 | |
| JP2013512195A5 (https=) | ||
| EP3793564A1 (en) | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma | |
| EP3787631A1 (en) | Modulators of orphan nuclear receptors for nash and other metabolic disorders | |
| TW202131917A (zh) | 併用醫藥 | |
| TW202202149A (zh) | Bcl-2/bcl-xl抑制劑之組合及相關用途 | |
| EP4719407A1 (en) | Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma |